UnitherPharmaceutical subcontractor

Unither Pharmaceuticals is a CDMO, which develops and manufactures single-dose dosage forms for its customers.

Investment date : 2022

Vehicle: NiXEN 3 UNI

Type of transaction : LBO

A spin-off from Sanofi in 1993, Unither is a pharmaceutical contract manufacturing organization (“CDMO”) specializing in the production and development of complex sterile liquid products for medical purposes.


The company is the world leader in blow-fill-seal (BFS) technology, which uses sterile unit doses to eliminate the need for preservatives. Unither has eight production sites in France, the United States, China and Brazil, as well as a dedicated research and development center in Europe.


NiXEN has decided to participate in this LBO as a co-investor alongside Keensight Capital, which is increasing its stake in Unither in order to support the management team in the next stages of the company’s international development.

With the addition of GIC and IK, and the support of our historical partners, Keensight and Parquest, we will continue to pursue our long-term strategy, continuing to satisfy our customers and leveraging our global presence
Éric Goupil, Executive Chairman of Unither Pharmaceuticals
(Source: Unither, press release dated October 26, 2022)